<DOC>
	<DOC>NCT01801917</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who have shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).</brief_summary>
	<brief_title>Efficacy and Tolerability of BAF312 in Patients With Polymyositis</brief_title>
	<detailed_description />
	<mesh_term>Polymyositis</mesh_term>
	<criteria>"definite" or "probable" for polymyositis at least three months before Baseline active disease as defined by elevated CK levels, or other enzymes, or MRI/biopsy if enzymes are normal, and persisting muscle weakness stable dose of corticosteroid for at least 2 weeks prior to Baseline and should not have received a medium or high dose in the last 8 weeks prior to study entry. patients treated with methotrexate must have been on a stable dose for at least 6 weeks prior to Baseline. Patients with overlap polymyositis, latestage polymyositis, or other types of myositis. Preexisting severe cardiac or pulmonary involvement, malignancy of any organ system or significant eye diseases. Uncontrolled diabetes mellitus or diabetes complicated with organ involvement. Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polymyositis, Myositis, PM</keyword>
</DOC>